Streetbeat News

Analyst Ratings

SGRY

Barclays analyst Andrew Mok initiates coverage on Surgery Partners (NASDAQ:SGRY) with an Equal-Weight rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:00 pm

MOH

Five analysts have recently updated their ratings on Molina Healthcare (NYSE:MOH), showing a mix of opinions. The average 12-month price target for MOH has been raised to $420.6, indicating a 10.25% increase from the previous target. Analysts from Barclays, Truist Securities, Wells Fargo, Cantor Fitzgerald, and UBS have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Molina Healthcare's financials show strong revenue growth, net margin, ROE, and ROA, but a high debt-to-equity ratio poses a challenge.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 12:00 pm

CRWD

Canaccord Genuity analyst Michael Walkley maintains a Buy rating on CrowdStrike Holdings (CRWD) and raises the price target from $300 to $400.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:00 pm

ROK

Recent analysis of Rockwell Automation (NYSE:ROK) by 9 analysts shows a mix of bullish and bearish sentiments, with a negative shift in the average 12-month price target by 3.97% to $306.89. Analysts from firms like Berenberg, JP Morgan, and Citigroup have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Rockwell Automation, a leader in automation, shows strong financial health with notable revenue growth, net margin, ROE, and ROA, despite challenges in debt management.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 12:00 pm

HON

Honeywell Intl (NASDAQ:HON) has received varied analyst ratings over the past three months, with a recent shift towards a more bullish outlook. The latest average price target is $223.0, marking a 7.04% increase from the previous target. Analysts from Berenberg, Barclays, RBC Capital, and Wells Fargo have updated their ratings and price targets, reflecting changes in market conditions and company performance. Honeywell, a global conglomerate, has shown notable revenue growth and profitability, with a strong financial overview including a high net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 12:00 pm

CNC

Six financial analysts have recently updated their ratings on Centene (NYSE:CNC), with a mix of bullish, somewhat bullish, and indifferent perspectives. The average 12-month price target for CNC is now $88.00, up from $78.60, indicating an 11.96% increase. Analysts from Barclays, Wells Fargo, Truist Securities, UBS, and Cantor Fitzgerald have adjusted their ratings and price targets, reflecting optimism about Centene's market performance. Centene, a managed-care organization, has shown strong financial indicators such as revenue growth, net margin, ROE, and ROA, outperforming industry averages. However, its debt-to-equity ratio is higher than the industry average, suggesting financial risk.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 12:00 pm

CRWD

Guggenheim analyst John Difucci maintains a Buy rating on CrowdStrike Holdings (CRWD) and raises the price target from $358 to $424.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 11:59 am

RDNT

Barclays analyst Andrew Mok initiates coverage on RadNet with an Equal-Weight rating and sets a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 11:59 am

CARA

Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Cara Therapeutics (NASDAQ:CARA) but lowers the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 11:58 am

PRVA

Barclays analyst Andrew Mok initiates coverage on Privia Health Group (PRVA) with an Equal-Weight rating and a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 11:57 am